RU 57708
Latest Information Update: 20 Jul 1998
Price :
$50 *
At a glance
- Originator Aventis
- Class Antibacterials; Ketolides; Macrolides
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 20 Jul 1998 No-Development-Reported for Bacterial infections in France (Unknown route)
- 18 Sep 1995 Preclinical development for Bacterial infections in France (Unknown route)